Our Company
A CONCEPT BORNE OUT OF NEED
After holding the hands of hundreds of children suffering from congenital heart disease, the founder of our technology felt there had to be a better way to provide care to children without having to rely on the highly restrictive MRI. Moreover, she still wanted to provide doctors with complete and full information that they need to monitor the heart state and make a confident diagnosis. It was this immediate need for change and compassion that eventually led to the idea of the VMS and the creation of Ventripoint.
ALWAYS TRUE TO OUR STORY
Ventripoint Diagnostics Ltd. (TSXV:VPT, OTCQB:VPTDF) is dedicated to improving diagnostic imaging by developing tools that offer higher performance, lower cost, faster turnaround times, and greater patient comfort.
Our flagship product, VMS+, enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. VMS+ is compatible with all standard echocardiology machines, bringing diagnosis and monitoring closer to the patient and providing clinicians with more timely results to support clinical decisions.
MANAGEMENT & BOARD OF DIRECTORS
Hugh MacNaught
Interim CEO, Director
Mr. MacNaught is a Fortune 100 trained executive with thirty years experience in the innovation, development, financing, and commercialisation of medical and life science technologies. He has worked in roles ranging from product development and manufacturing to finance, business development and executive management. His background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging. His familiarity with research translation and technology development within early stage companies includes several years as a venture capitalist and founding, leading and financing technology ventures.
During the past decade Hugh has provided guidance to university spin-outs, corporate venturing initiatives and served as a business mentor at several Canadian universities. He has served as a director for corporations and not-for-profit agencies, including serving as the Audit Chair for Genome Prairie. He sat on the Technology Commercialization Committee for the Alberta Heritage Foundation for Medical Research, and is currently a member of the Core Evaluation Team for the GAPP Program at Genome Canada.
Dr. George Adams
Chairman, Member of Nominating & Corporate Governance & Audit Committees
Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010. He was Chairman of Sernova Corp (TSXV:SVA) and President and CEO of the UT Innovations Foundation from 1999 until 2004. Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service. He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies. .Dr. Adams was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009. Dr Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.
Robert Hodgkinson
Director
Mr. Hodgkinson has over 40 years of experience in public and venture capital markets. He has raised $150M+ of capital for numerous companies and is an experienced corporate director, senior executive and adviser. He has been instrumental in successful merger and acquisitions in oil and gas transactions totaling $500M+ and has acted as a principal and agent in corporate structuring/restructuring.
Fiona Fitzgerald
Director
Ms. Fitzgerald is the current National Zone Leader for Cytiva Life Science and accounts for all the commercial products in Canada. She has over two decades of experience working with GE in Canada and made the transition to Cytiva in March 2020. Ms. Fitzgerald has sat on multiple Government of Canada Federal Committees including NSERC’s CREATE program, which she later chaired, and several NSERC Centre of Excellence Evaluation committees. She currently holds three board memberships in CIMTEC, MDCC, and is on the Advisory Board for the Centre of Bioengineering and Biotechnology in Waterloo University. Ms. Firzgerald seeks to further develop the Life Sciences industry in Canada and will be focusing her efforts in the growth and development of Ventripoint.
Randy AuCoin
Director
Randy AuCoin is currently the President and CEO of Exact Imaging, the world leader in high-frequency ultrasound for early detection of prostate cancer. Mr. AuCoin has raised over $50 million of venture capital and has had senior roles in Quinton Electrophysiology Corporation, DICOMIT, VisualSonics Inc., and Imagistx Inc. He has extensive experience in fund raising, sales and marketing, operations, and finance. Mr. AuCoin aims to guide Ventripoint towards becoming the standard-of-care for cardiac ultrasound diagnostics.
CLINICAL ADVISORY BOARD
Howard Leong-Poi
Dr. Howard Leong-Poi is presently the head of the Division of Cardiology, as well as Program Director, of the Heart and Vascular Program at St. Michael’s Hospital in Toronto, Ontario. Dr. Leong-Poi is also a practicing Physician within the Cardiology department at St. Michael’s Hospital with over 20 years of experience. Along with his mentioned roles, Dr. Leong-Poi is a Full Professor of Medicine at the University of Toronto. Dr. Leong-Poi has served on multiple grand review panels, such as the CancerCare Manitoba Foundation, Swiss National Science Foundation, Canadian Foundation for Innovation, and others. He is a member of the Institute of Medical Sciences, Canadian Society of Echocardiography, Canadian Cardiovascular Society, and other notable associations. Dr. Leong-Poi has received numerous international awards, including the 2017 Feigenbaum Lecturer, recipient of the 2005 William W. Parmley Young Author Achievement Award, and 1st prize for the Research Award Competition for the American Society of Echocardiography.
Dr. Jose Banchs
Dr. Jose Banchs is the current Director of Echocardiography at the University of Colorado’s Anschutz Medical Campus, as well as Professor of Medicine in the Cardiology Division at the University of Colorado. He is a diplomate of the American Board of Internal Medicine in Cardiovascular Disease and the National Board of Echocardiography. He is a Fellow of the American College of Cardiology and the American Society of echocardiography where he is serving currently as a member of the board of directors for the American Society of Echocardiography and has served in several societal writing groups. He has been a consultant for numerous organizations across the imaging industry in the United States. He has been recognized as Faculty Teacher of the Year Award for multiple years in a row in his previous faculty appointment with the University of Texas. Dr. Banchs has an extensive list of published work within the biomedical field, such as research articles, book chapters, and editorials.
Dr. Gregory Skinner
Dr. Gregory Skinner is a Consultant Paediatric Cardiologist who works out of the East Midlands Congenital Heart Centre in Leicester, UK where he is the Deputy Head of Service and Clinical Lead for Paediatric Cardiology. Dr. Skinner is certified in Congenital Heart Disease Echocardiography by the European Society of Cardiovascular Imaging. Along with general paediatric cardiology, Dr. Skinner specializes in advanced imaging, paediatric and congenital cardiac x-ray computed tomography (CT), and magnetic response imaging. He also has a special interest in 3D printing for complex congenital heart defects. He is an author and editor of Emergencies in Clinical Medicine (first and second editions), and has been featured in multiple publications.